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Introduction 
Random assignment of individual participants in clinical trials entails two separate steps: (i) 
generating an unbiased allocation schedule; and (ii) using the schedule, without 
foreknowledge of upcoming allocations, to assign participants to treatment comparison 
groups. Both of these steps were implemented in two controlled trials done under the aegis 
of the British Medical Research Council (MRC) in the 1940s (Chalmers 2010): the trial of 
patulin for the common cold (MRC 1944; Clarke 2004), and the better known trial of 
streptomycin for pulmonary tuberculosis (MRC 1948; Chalmers 2010). However, the two 
separate steps needed to achieve unbiased treatment assignment were not identified clearly 
until 1955, when Austin Bradford Hill distinguished them in the 6th edition of his book 
Principles of Medical Statistics (Chalmers 2005). Shortly thereafter, David Cox (1958) and 
Peter Armitage (1960) emphasized the importance of implementing an unbiased allocation 
by using sealed envelopes to conceal an upcoming allocation until after a participant had 
been irrevocably entered into a trial. Despite early recognition of the importance of the two 
separate steps in unbiased allocation, however, no widely accepted term denoting the 
process of concealing upcoming allocations had been adopted more than half a century 
later.  
 
Methodological terminology is often imprecise. Researchers may abandon the intended 
meaning, even with common terminology. For example, the terms ‘nomogram’ and ‘case-
control’ are widely misused in research (Grimes 2008; Grimes 2009). Jargon (for example, 
‘gold standard’) leads to confusing and meaningless terms (Conti 1994). Clearly, accurate 
communication requires unambiguous terminology. 
 
The plethora of terminology surrounding randomized trials presents particular challenges. 
Trials suffer from a great deal of arcane terminology. Some examples include ‘random 
permuted blocks’, ‘participant retention’, ‘double- and triple-blinding’, ’masking’, ‘interim 
analyses’, ‘alpha spending’, ‘urn randomization’, ‘biased-coin randomization’, and ‘group 
sequential trials’. While most of these represent important trial processes and methods, 
even the most common terms may confuse or obfuscate. For example, although blinding 
terminology seems well ensconced, even apparently simple terminology like ‘double-
blinding’ elicits inconsistent connotations.  When investigators examined physician 
interpretations and textbook definitions of ‘double-blinding’, they found 17 unique 
interpretations and nine different definitions (Devereaux et al. 2001). Reporting only 
‘double-blinding’ without proper elaboration leads to ambiguity (Schulz et al. 2002; Schulz 
and Grimes 2002).  
 
Terminology serves another important function. It can indicate a critical methodological 
process that might otherwise be neglected in the conduct of a study unless highlighted by 
terminology. Because lack of attention to detail can impact on the conduct of trials, lack of 
appropriate terminology may cause harm if an important trial function has been 
inadequately addressed.  
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Despite the sheer volume of terminology in randomized trials, we discovered a 
terminological gap when we were assessing the quality of treatment allocation in reports of 
controlled trials published in journals of obstetrics and gynecology in the 1990s (Schulz et 
al. 1994). When writing up that research, we introduced the term ‘allocation concealment’ 
(Schulz et al. 1994) to denote the second of the two essential steps in achieving unbiased 
allocation to treatment comparison groups. In this article we have reviewed the precursors 
of the term ‘allocation concealment’, and its subsequent evolution and adoption from the 
mid-1990’s onwards. 
 
Recognizing the need for randomization terminology 
Over the years, books on randomized trials provided excellent and detailed descriptions of 
methods to generate randomized allocation sequences. These sequences formed 
randomization lists. Chapters and sections of chapters had titles such as ‘methods of 
randomization’, ‘constrained randomization’, ‘adaptive randomization’, ‘unequal treatment 
allocation’, ‘permuted block designs’, ‘biased-coin design’, ‘urn design’, and ‘stratified 
randomization’.  
 
In books published before we suggested the term ‘allocation concealment’ in 1994, chapters 
describing the mechanisms for implementing allocation sequences were rare. Moreover, 
scant information was devoted to those mechanisms elsewhere in the books. For example, 
one of the most detailed discussions we found was a ‘Mechanics of Randomization’ section 
from a book published in 1985, but it was less than two pages in a 17-page chapter 
(Friedman et al. 1985). 
   
As we have noted, some trialists recognized the importance of mechanisms for 
implementing allocation sequences long ago, including the use of sealed envelopes (Cox 
1958; Armitage 1960; Hill 1962; Chalmers 2005). In meetings with IC and KS in 1992, 
Richard Peto noted that he had emphasized (Peto 1987) that randomization should 
incorporate a mechanism to prevent investigators, health care providers, and participants 
from foreknowledge of upcoming assignments, but he had not come up with a term for the 
mechanism. 
 
‘Randomization blinding’ 
Thomas Chalmers and colleagues provided key inspiration. In the early 1980s, they had not 
only recognised the importance of the assignment mechanism, but had termed it 
‘randomization blinding’ (Chalmers et al. 1981). They suspected that bias introduced into 
“…studies in which assignment of controls is less blinded may be explained by bias in the 
selection or rejection of patients when the treatment to be given is known or suspected at 
the time of assignment” (Chalmers et al. 1983). Thus, without adequate ‘randomization 
blinding’, selection bias could occur.  To investigate their suspicions they used trials of 
treatments for acute myocardial infarction, using case-fatality rates as the outcome. They 
defined ‘blinded randomization’ as ‘opaque envelopes’, ‘a telephone call to a statistical 
center’, or ‘a prearranged order of blinded medications labeled consecutively by the 
pharmacy’ (Chalmers et al. 1983). They defined ‘unblinded randomization’ as “assignment 
from an open table of random numbers, according to date of birth or chart number, or by 
some other variably random system in which patients could present for study in a chance 
order but be selected or rejected after the physician knew the treatment assignment” 
(Chalmers et al. 1983). They found that trials using unblinded randomization yielded larger 
estimates of treatment effects, which were more often statistically significant, than those in 
trials using blinded randomization. Their findings provided the strongest evidence at that 
time that ‘unblinded randomization’ was associated with empirical evidence suggestive of 
bias in ‘randomized’ trials.  
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The ‘blinding’ terms ‘blinded randomization’ and ‘unblinded randomization’ are confusing 
because they address a mechanism within treatment allocation, not whether a trial is 
subsequently blinded to treatment identity. For example, a trial may have ‘blinded 
randomization’ as defined by Thomas Chalmers and his colleagues (Chalmers et al. 1983), 
but, after allocation, investigators and participants may not have been blinded to treatment 
assignments. Perhaps because of confusion between ‘randomization blinding’ and ‘treatment 
blinding’ or ‘outcome measurement blinding’, adoption of the ‘blinded randomization’ and 
‘unblinded randomization’ terminology remained rare. Moreover, their definitions of ‘blinded 
randomization’ and ‘unblinded randomization’ were insufficiently specific. For example, 
although referring to “opaque envelopes”, they did not mention additional precautions such 
as sequential numbering, and their definitions and analysis neglected the common 
occurrence of published reports that had not described the implementation mechanism of 
the random allocation schedule. 
 
As noted by commentators (Gillman and Runyan 1984), the analysis used by Thomas 
Chalmers and his colleagues (1983) could not take account of the different types of 
treatments in their blinded and unblinded randomization categories, thus leaving their 
results potentially confounded by treatment. For example, most beta-blocker trials were in 
the blinded randomization group while most antithrombotic agent trials were in the 
unblinded randomization group (Gillman and Runyan 1984). Second, they did not account 
for other trial characteristics, such as generation of the allocation sequence and blinding of 
treatments. Third, their study left unanswered the status of all those trials whose published 
reports did not provide any information about the implementation mechanism for random 
allocation. That was a critical issue, because poorly reported trials then predominated in the 
literature (Mosteller et al. 1980; DerSimonian et al. 1982; Altman and Doré 1990; Tyson et 
al. 1983), as they do now (Hopewell et al. 2010). 
 
‘Bias-reducing allocation’ 
In 1990, Altman and Doré improved terminology and definitional clarity (Altman and Doré 
1990). Instead of using the terms ‘blinded randomization’ and ‘unblinded randomization’, 
they termed the process ‘bias-reducing allocation’, using this definition: “The mechanism of 
treatment allocation should be designed to avoid bias: suitable methods are central 
randomization, coded drugs prepared by the pharmacy, and use of a series of numbered 
opaque sealed envelopes”. Their categorization of reports was based on these definitions as 
‘yes’, ‘no’, or ‘not specified’.  
 
The Altman and Doré terminology and analysis were improvements over that suggested by 
Thomas Chalmers and colleagues (1983) because they avoided derivatives of the term 
‘blind’, specified that envelopes should be sequentially numbered and sealed, and included a 
‘not specified’ option. The latter applied to almost half of the responses in their study and to 
three-quarters of the reports of randomized trials in PubMed (Hopewell et al. 2010). For 
anyone appraising the quality of the literature, this ‘not specified’ category provides an 
important perspective for evaluating quality. 
 
‘Allocation concealment’ 
We needed a replacement term for ‘randomization blinding’. Although Altman and Doré had 
improved the terminology by introducing ‘bias-reducing allocation’, some confusion 
remained. For example, ‘bias-reducing allocation’ could be confused with the process of 
generating a random allocation sequence, or indeed, the entire randomization process. 
Accordingly, we sought further terminological improvement in our review of reports of trials 
in obstetrics and gynecology (Schulz et al. 1994). 
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Without any recognized method for introducing terminology, we relied upon a subjective, 
iterative, discussion process. We avoided any terminology associated with ‘blinding’ and 
explored the dictionary for words to capture the assignment process. After long 
deliberations, KS, IC, DG, and DA proposed ‘allocation concealment’. This implied a 
mechanism to prevent foreknowledge of upcoming assignments which avoid any reference 
to ‘blinding’. We first used the term ‘allocation concealment’ in 1994 (Schulz et al. 1994). 
Because the term was new, we explained our rationale for preferring ‘allocation 
concealment’ in detail:   
 
“The reduction of bias in trials depends crucially upon preventing foreknowledge of 
treatment assignment. Concealing assignments until the point of allocation 
prevents foreknowledge, but that process has sometimes been confusingly referred 
to as 'randomization blinding'. This term, if used at all, has seldom been 
distinguished clearly from other forms of blinding (masking) and is unsatisfactory 
for at least three reasons. First, the rationale for generating comparison groups at 
random, including the steps taken to conceal the assignment schedule, is to 
eliminate selection bias. By contrast, other forms of blinding, used after the 
assignment of treatments, serve primarily to reduce ascertainment bias. Second, 
from a practical standpoint, concealing treatment assignment up to the point of 
allocation is always possible, regardless of the study topic, whereas blinding after 
allocation is not attainable in many instances, such as in trials conducted to 
compare surgical and medical treatments. Third, control of selection bias pertains 
to the trial as a whole, and thus to all outcomes being compared, whereas control 
of ascertainment bias may be accomplished successfully for some outcomes, but 
not for others. Thus, concealment up to the point of allocation of treatment and 
blinding after that point address different sources of bias and differ in their 
practicability. In light of those considerations, we refer to the former as 'allocation 
concealment' and reserve the term 'blinding' for measures taken to conceal group 
identity after allocation” (Schulz et al. 1994). 
 
We deemed the following approaches as adequate allocation concealment: “central 
randomization (e.g., by telephone to a trials office); a pharmacy [drugs or study products 
prepared by the pharmacy]; numbered or coded containers; and sequentially numbered, 
opaque, sealed envelopes” (Schulz et al. 1994). We considered non-random, transparent 
(often called ‘systematic’) approaches, such as “alternate assignment and assignment by 
odd/even birthdate or hospital number” as inadequate allocation concealment (Schulz et al. 
1994). We deemed as ‘unclear allocation concealment’ those approaches in which authors 
had not reported any allocation approach or reported an approach that was not captured by 
the ‘adequate’ or ‘inadequate’ concealment categories. Of 206 trial articles, only 23% used 
adequate allocation concealment, while 48% had not described any mechanism to allocate 
treatments (Schulz et al. 1994; Schulz et al. 1995a). 
 
Showing that ‘allocation concealment’ matters 
Having defined allocation concealment, our next line of inquiry was to investigate whether 
this construct, as implemented in trials, was associated with indicators of bias. Prior work by 
Thomas Chalmers and his associates had shown that ‘unblinded randomization’ was 
associated with larger estimates of effect compared to ‘blinded randomization’ (Chalmers et 
al. 1983). However, as noted above, their study had several weaknesses.  
 
We addressed those weaknesses by using multiple logistic regression statistical models to 
analyze 250 trials in 33 meta-analyses published in the Cochrane Pregnancy and Childbirth 
Database (Schulz et al. 1995b). To address confounding by treatment we examined the 
association between ‘allocation concealment status’ and estimates of treatment effects 
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within the same treatments across the 33 meta-analyses. To address confounding from 
other trial characteristics we controlled for the method used to generate the allocation 
sequence, exclusions after allocation, and blinding of outcome assessments. Lastly, we 
analyzed trials with unclear allocation concealment (largely those trials for which the 
published reports had not provided any description of allocation concealment).  
 
Using the substantial amount of relevant data generated by the Cochrane Pregnancy and 
Childbirth Group (Chalmers 1988) and the increased statistical computing power that had 
become more readily available we were able to address weaknesses in the analyses 
reported by Tom Chalmers and his colleagues (1983) more than a decade earlier. Our more 
detailed analyses showed that allocation concealment was indeed associated with trial 
results: on average, estimates of treatment effects were 41% larger in trials with 
inadequate allocation concealment and 33% larger in those with unclear allocation 
concealment compared to trials with adequate allocation concealment (Schulz et al. 1995b). 
Moreover, as a further indication of likely bias, we found that the results of trials with 
reports of inadequate allocation concealment were more heterogeneous than those with 
adequate allocation concealment (Schulz et al. 1995b). Our study of randomized trials in 
pregnancy and childbirth provided empirical evidence that poor allocation concealment was 
likely associated with bias.  We were pleased that the importance of our study was 
recognized explicitly by others (Figure 1). 
 
Moher replicated our study in additional medical specialties and found similar results (Moher 
et al. 1998). Repeatedly, evidence was found that allocation concealment mattered. This 
empirical evidence gave substantial impetus to calls for increased attention to improved 
reporting, especially on critical items such as allocation concealment. Others had called for 
improved reporting, but this research provided tangible evidence that indications of poor 
methods were indeed likely associated with bias. As Drummond Rennie wrote in a 1995 
editorial in JAMA commenting on the empirical evidence of bias in our paper, “These 
admonitions are not new; what is new is the demonstration of the consequences of their 
neglect” (Rennie 1995).  
 
Establishment and adoption of allocation concealment terminology 
Having created the term and validated the concept of ‘allocation concealment’, launching 
the terminology extended beyond journal publications. We introduced the terminology and 
concepts into various organizations and groups. Indeed, scientific overlap among all of us 
aided the process, initiated the Cochrane Centre, which spawned the Cochrane 
Collaboration. Iain Chalmers enlisted Schulz as the first visiting research fellow at the 
Cochrane Centre, where they collaborated with Grimes, Altman, and Hayes. Altman and 
Schulz led the initial development of the Cochrane Statistical Methods Group.  
 
Independently, Moher was organizing a meeting to discuss evaluation of the quality of 
randomized trials, and he invited Chalmers to attend. However, because our analysis had 
not been published at the time, Chalmers suggested that Schulz should attend and promote 
adoption of the term ‘allocation concealment’ and present the evidence that bias is likely to 
be associated with inadequate allocation concealment. Moher’s meeting resulted in a 
reporting guideline entitled Standards Of Reporting Trials (SORT) (The Standards of 
Reporting Trials Group 1994). Following a further meeting to which Moher and Schulz 
contributed, SORT morphed into another trial reporting guideline - the Consolidated 
Standards of Reporting Trials (CONSORT) Statement (CONSORT Group 1996). This in turn 
blosomed into a worldwide initiative to improve the reporting of medicial research – the 
EQUATOR Network (Altman and Simera 2015). 
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Schulz promoted appreciation of the importance of allocation concealment with personal 
accounts of problems he had encountered with assignment schemes and suggested 
methods for improving allocation concealment (Schulz 1995). Altman joined Moher and 
Schulz as members of the CONSORT Executive and coauthors of succeeding CONSORT 
Statements (Moher et al. 2001; Schulz et al. 2010a; Schulz et al. 2010b), and Grimes 
became part of the CONSORT Group, and we published a paper setting out the rationale for 
allocation concealment and providing examples of good reporting (Altman et al. 2001). And 
in his book on cluster randomized trials, Hayes extended the need for allocation 
concealment in those trials (Hayes and Moulton 2009). The SPIRIT (Standard Protocol 
Items: Recommendations for Interventional Trials) guidelines for the content of protocols 
for randomized trials (Chan et al. 2013a; Chan et al. 2013b) drew heavily on CONSORT 
Statement.  
 
A PubMed search for the term ‘allocation concealment’ in ‘any field’ during the 22 years 
before our 1994 paper in JAMA yielded no citations, compared with 1471 citations over the 
22 years between 1995 and 2016. The annual number of citations climbed steadily before 
plateauing around 2012 (Figure 2).  
 
Using Google Scholar to search for ‘allocation concealment’ anywhere in articles published 
during the 22 years before our 1994 JAMA paper yielded 25 matches, most of which were 
mistakes. Thirty thousand matches were retrieved from articles published after 1994, and 
the annual number of matches has increased through 2016 (Figure 3).  
 
Concluding reflections 
The term ‘allocation concealment” has been widely adopted by authors and editors.  
We have less evidence that rigorous definitions are being used for allocation concealment. 
Although the Cochrane Collaboration uses highly precise definitions (Higgins et al. 2011), 
we suspect that many authors and editors define allocation concealment imprecisely, similar 
to their imprecise use of other trial terminology (Devereaux et al. 2001). Furthermore, 
‘allocation concealment’ could refer to blinding of outcome assessors.  For example, Cox 
noted in 1958 that “The final stage in which concealment may be advisable is in the making 
of the observation itself” (Cox 1958). Although the term ‘allocation concealment’ might still 
be improved to avoid occasional misconceptions about its meaning (for example, extending 
it to ‘allocation schedule concealment’), we assume that it has been widely adopted by 
authors and editors because they find the 2-word term useful. 
 
Our modeling and methodological approach (Schulz et al. 1995b) to examine the 
associations between dimensions of methodological quality and estimates of treatment 
effects has gained recognition and has led to confirmatory replications. As stated by two 
prominent methodological researchers (Juni and Egger 2005): 
 
In more recent years, the debate has shifted from anecdotal evidence of bias in 
single trials to more sophisticated ‘meta-epidemiological’ research, based on many 
trials and meta-analyses (Sterne et al. 2002). Schulz and colleagues (Schulz et al. 
1995) pioneered this approach when they assessed the methodological quality of 250 
trials from 33 meta-analyses from the Cochrane Pregnancy and Childbirth Database 
and examined the association between dimensions of trial quality and estimated 
treatment effects (Juni and Egger 2005).  
 
This general approach has even been used by Savovic and her colleagues (2012) to 
incorporate multiple meta-epidemiological studies in an analysis. Although these 
investigations of associations of allocation concealment extended to other subject areas 
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have yielded the same directions of association as our 1995 analysis (Schulz et al. 1995a), 
the strength of the associations has varied (Savovic et al. 2012).  
 
Our research on empirical evidence of bias related to allocation concealment provided 
impetus for the initial development of the SORT and CONSORT reporting guidelines for 
randomized trials (The Standards of Reporting Trials Group 1994; CONSORT Group 1996; 
Moher et al. 2001; Schulz et al. 2010a; Schulz et al. 2010b), and the adoption of CONSORT 
has been associated with improved reporting of randomized trials (Turner et al. 2012a; 
Turner et al. 2012b). We believe that heightened attention to the process of allocation 
concealment has also improved the conduct of randomized trials. Indeed, compared with 
randomized trials published before 1990 those published between 2006 and 2012 were 
more likely to have reported adequate allocation concealment (Peters et al. 2017; Reveiz et 
al. 2015). However, much room for improvement remains (Chan and Altman 2005; 
Hopewell et al. 2010). 
 
Our identification and validation of allocation concealment represents one step towards 
better conduct and reporting of randomized trials. Further steps must include expanded and 
enhanced medical research training in design, conduct, and reporting of trials. 
 
Legends 
Figure 1: Plaque recording the 1996 CDC and ATSDR Statistical Science Award presented to 
Schulz, Chalmers, Hayes and Altman for the Best Applied Paper.  
Figure 2: Number of “allocation concealment” citations retrieved using PubMed, by year, 
1994 to 2016. 
Figure 3: Number of “allocation concealment” citations (anywhere in article) retrieved using 
Google Scholar, by year, 1994 to 2016. 
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